Repligen Names New CEO
Repligen is a supplier of protein affinity ligands for Protein A media for bioprocess-manufacturing purification products. Customers include Merck LifeScience and GE Healthcare. The company also offers the OPUS chromatography columns for biologics manufacturing. In 2014, revenues declined 6.8% to $63.5 million. Bioprocessing product revenue increased 27.3% to $60.4 million. GE Healthcare accounted for 38% of total revenues.
Waltham, MA 1/21/15—Repligen, a provider of consumables products for manufacturing biological drugs, has appointed COO Tony J. Hunt as CEO, effective May 21. He succeeds Walter C. Herlihy, PhD, who will retire as president and CEO. “We are delighted to promote our COO, Tony Hunt, a seasoned and successful bioprocessing-industry executive, to the position of CEO,” said Karen A. Dawes, chair of the Board. “Tony joined Repligen in the spring of 2014 as chief operating officer and has quickly made a very positive impact as a leader by expanding our commercial footprint and effectively integrating our acquisition of Refine Technologies into our operations.” Before joining Repligen, Mr. Hunt served as president of BioProduction at Life Technologies.
